GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (NAS:TTNP) » Definitions » E10

Titan Pharmaceuticals (Titan Pharmaceuticals) E10 : $-807.16 (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Titan Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Titan Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $-1.240. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-807.16 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 24.40% per year. During the past 5 years, the average E10 Growth Rate was 21.90% per year. During the past 10 years, the average E10 Growth Rate was 21.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Titan Pharmaceuticals was 30.80% per year. The lowest was 4.50% per year. And the median was 16.50% per year.

As of today (2024-05-28), Titan Pharmaceuticals's current stock price is $6.4173. Titan Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $-807.16. Titan Pharmaceuticals's Shiller PE Ratio of today is .


Titan Pharmaceuticals E10 Historical Data

The historical data trend for Titan Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals E10 Chart

Titan Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,161.34 -1,953.94 -1,370.57 -716.59 -844.01

Titan Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -913.31 -900.36 -882.28 -844.01 -807.16

Competitive Comparison of Titan Pharmaceuticals's E10

For the Biotechnology subindustry, Titan Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Titan Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Titan Pharmaceuticals's Shiller PE Ratio falls into.



Titan Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Titan Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.24/131.7762*131.7762
=-1.240

Current CPI (Mar. 2024) = 131.7762.

Titan Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -198.002 100.560 -259.468
201409 -180.001 100.428 -236.188
201412 -216.002 99.070 -287.312
201503 -864.007 99.621 -1,142.886
201506 -396.003 100.684 -518.293
201509 -324.003 100.392 -425.294
201512 -396.003 99.792 -522.923
201603 -324.003 100.470 -424.960
201606 1,980.020 101.688 2,565.880
201609 -432.003 101.861 -558.876
201612 -539.860 101.863 -698.398
201703 -576.005 102.862 -737.917
201706 -612.005 103.349 -780.342
201709 -720.006 104.136 -911.116
201712 -630.491 104.011 -798.797
201803 -444.004 105.290 -555.698
201806 -150.001 106.317 -185.921
201809 -408.004 106.507 -504.806
201812 -161.601 105.998 -200.902
201903 -204.002 107.251 -250.653
201906 -228.002 108.070 -278.018
201909 -108.001 108.329 -131.377
201912 -41.211 108.420 -50.089
202003 -40.600 108.902 -49.128
202006 -29.200 108.767 -35.377
202009 -30.400 109.815 -36.480
202012 -8.643 109.897 -10.364
202103 -5.600 111.754 -6.603
202106 -3.400 114.631 -3.909
202109 -3.800 115.734 -4.327
202112 -5.200 117.630 -5.825
202203 -4.800 121.301 -5.215
202206 -3.600 125.017 -3.795
202209 -3.600 125.227 -3.788
202212 -3.390 125.222 -3.567
202303 -2.230 127.348 -2.308
202306 -2.200 128.729 -2.252
202309 -0.400 129.860 -0.406
202312 -2.610 129.419 -2.658
202403 -1.240 131.776 -1.240

Add all the adjusted EPS together and divide 10 will get our e10.


Titan Pharmaceuticals  (NAS:TTNP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Titan Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Titan Pharmaceuticals (Titan Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.
Executives
Seow Gim Shen 10 percent owner NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
Sire Group Ltd. 10 percent owner NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
David Natan director 11190 BISCAYNE BLVD, MIAMI FL 33181
Matthew Charles Mcmurdo director 1047 SEWARD AVE., WESTFIELD NJ 07090
Peter Louis Chasey director 3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129
Eric Howard Greenberg director 710 CARLYLE ST, WOODMERE NY 11598
Avraham Ben-tzvi director 44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544
Katherine Beebe director, officer: President and COO 400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080
Choon Hau Choong 10 percent owner NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060
David E. Lazar director, 10 percent owner, officer: Chief Executive Officer VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000
Activist Investing Llc other: Member of 10% owner group 1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036
Joseph A Akers director 630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111
James R Mcnab director C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Marc Rubin director, officer: Executive Chairman C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Dane Hallberg officer: See Remarks 400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080